secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stoke Therapeutics, Inc. (STOK)
CIK:        0001623526
Form:       8-K
Filed at:   2026-03-27T23:59:59+00:00
Accession:  0001193125-26-129168
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stoke Therapeutics dismisses KPMG, appoints Ernst & Young as auditor
--------------------------------------------------------------------

- On March 23, 2026, Audit Committee dismissed KPMG as independent registered public accounting firm.
- KPMG's reports for FY2024 and FY2025 contained no adverse opinion, disclaimer, or qualification.
- No disagreements or reportable events occurred during fiscal years 2024-2025 or interim period through March 23, 2026.
- Audit Committee approved engagement of Ernst & Young LLP as independent auditor for FY ending December 31, 2026.
- Company had no prior consultations with EY regarding accounting matters described in Item 304(a)(2).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1623526/000119312526129168/0001193125-26-129168-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1623526/000119312526129168/d119051d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-129168

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer